T.M. Kim

发表

Independent Poor Prognostic Factors for True Progression after Radiation Therapy and Concomitant Temozolomide in Patients with Glioblastoma: Subependymal Enhancement and Low ADC Value

C. Sohn, S.H. Choi, S.-H. Park, 2015, American Journal of Neuroradiology.

Osimertinib plus platinum–pemetrexed in newly diagnosed epidermal growth factor receptor mutation-positive advanced/metastatic non-small-cell lung cancer: safety run-in results from the FLAURA2 study

P. Jänne, D. Planchard, S. Kim, 2021, ESMO open.

Oncogenic BRAF fusions in mucosal melanomas activate the MAPK pathway and are sensitive to MEK/PI3K inhibition or MEK/CDK4/6 inhibition

H. Kim, B. Cho, Z. Zheng, 2017, Oncogene.

Prognostic Predictions for Patients with Glioblastoma after Standard Treatment: Application of Contrast Leakage Information from DSC-MRI within Nonenhancing FLAIR High-Signal-Intensity Lesions

S.H. Kim, S.H. Choi, J. Won, 2019, American Journal of Neuroradiology.

529P A phase Ib trial of belvarafenib in combination with cobimetinib in patients (pts) with RAS- or RAF- mutated (m) solid tumors: Updated safety data and indication-specific efficacy results

S. Shin, C. Ahn, Y. Kim, 2021, Annals of Oncology.

matin) by preventing methylation of DNA and histones by employing 5-azacytidine or tricho- statin A and noticed enhanced self-renewal of murine bone marrow (BM)–derived HSCs that were transplanted into lethally irradiated recipi-

Chung, L. Boyer, G. Cimino, 2009 .

Gene expression signatures associated with the in vitro resistance to two tyrosine kinase inhibitors, nilotinib and imatinib

H. K. Kim, S. Ha, S-H. Jung, 2011, Blood cancer journal.

A small subunit processome protein promotes cancer by altering translation

P. Park, R. Carroll, L. Menon, 2014, Oncogene.

Gene expression signatures associated with the resistance to imatinib

H. K. Kim, S. Ha, H. Namkoong, 2006, Leukemia.

Cluster Analysis of DSC MRI, Dynamic Contrast-Enhanced MRI, and DWI Parameters Associated with Prognosis in Patients with Glioblastoma after Removal of the Contrast-Enhancing Component: A Preliminary Study

S.H. Choi, J. Won, S. Park, 2022, American Journal of Neuroradiology.

LBA52 Tepotinib + osimertinib for EGFRm NSCLC with MET amplification (METamp) after progression on first-line (1L) osimertinib: Initial results from the INSIGHT 2 study

C. Dooms, F. de Marinis, J. Mazières, 2022, Annals of Oncology.

1173P Early safety, tolerability, and efficacy of REGN5093 in patients (pts) with MET-altered advanced non-small cell lung cancer (aNSCLC) from a first in human (FIH) study

A. Drilon, M. Awad, J. Gray, 2022, Annals of Oncology.

Dynamic Contrast-Enhanced MR Imaging of Nonenhancing T2 High-Signal-Intensity Lesions in Baseline and Posttreatment Glioblastoma: Temporal Change and Prognostic Value

C. Sohn, S.H. Choi, J. Won, 2019, American Journal of Neuroradiology.

EP08.02-140 MET Biomarker-based Preliminary Efficacy Analysis in SAVANNAH: savolitinib+osimertinib in EGFRm NSCLC Post-Osimertinib

L. Sequist, S. Novello, F. de Marinis, 2022, Journal of Thoracic Oncology.

Co-clinical trials demonstrate predictive biomarkers for dovitinib, an FGFR inhibitor, in lung squamous cell carcinoma

S. Paik, M. Ahn, B. Cho, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

988P Phase I/II study of mobocertinib in EGFR exon 20 insertion (ex20ins) + metastatic NSCLC (mNSCLC): Updated results from platinum-pretreated patients (PPP)

P. Jänne, Gregory Riely, T. Mekhail, 2022, Annals of Oncology.

OA04.03 Mobocertinib in NSCLC With EGFR Exon 20 Insertions: Results From EXCLAIM and Pooled Platinum-Pretreated Patient Populations

P. Jänne, Gregory Riely, E. Felip, 2021 .

35P Real-world treatment outcomes of amivantamab in pre-approval access (PAA) participants with advanced non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations (ex20ins)

M. Hochmair, A. Spira, A. Panaccione, 2022, Annals of Oncology.

MA07.09 BBT-176, a 4th generation EGFR TKI, for Progressed NSCLC after EGFR TKI Therapy: PK, Safety and Efficacy from Phase 1 Study

S. Ou, D-W. Kim, T.M. Kim, 2022, Journal of Thoracic Oncology.

790MO Phase I study of fianlimab, a human lymphocyte activation gene-3 (LAG-3) monoclonal antibody, in combination with cemiplimab in advanced melanoma (mel)

I. Lowy, O. Hamid, V. Janković, 2022, Annals of Oncology.